Danske Bank’s Jasper Therapeutics JSPR Stock Holding History

Danske Bank’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$38	–	1526
2024 Q3	$38	Buy	+2	New	+$40	﹤0.01%	1488

Other funds holding JSPR

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Danske Bank's JSPR Position: Q4 2024 in Review

Danske Bank sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 2 shares — an estimated $38 sold.

Danske Bank first reported a position in JSPR in Q3 2024 and held it in 1 quarter. The position peaked at $38 in Q3 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

Danske Bank reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 2 Jasper Therapeutics shares in Q4 2024, an estimated $38.
Danske Bank first reported a position in Jasper Therapeutics in Q3 2024 and held it in 1 quarter.
Danske Bank's Jasper Therapeutics position peaked at $38 in Q3 2024.
87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.